Can you provide the last earnings date for MOONLAKE IMMUNOTHERAPEUTICS?
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) last reported earnings on 1/8/2026.
NASDAQ:MLTX • KY61559X1045
Past quarterly earnings results for MOONLAKE IMMUNOTHERAPEUTICS (MLTX), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.92 | -1.01 | 9.02% | -27.50% | - | - | ||
| Q3 2025 | -1.10 | -0.90 | -22.75% | -96.43% | - | - | ||
| Q2 2025 | -0.87 | -0.74 | -18.26% | -123.08% | - | - | ||
| Q1 2025 | -0.63 | -0.77 | 17.89% | -186.36% | - | - | ||
| Q4 2024 | -0.72 | -0.61 | -18.11% | -500.00% | - | - | ||
| Q3 2024 | -0.56 | -0.44 | -26.10% | -211.11% | - | - | ||
| Q2 2024 | -0.39 | -0.28 | -37.92% | -69.57% | - | - | ||
| Q1 2024 | -0.22 | -0.20 | -11.55% | 4.35% | - | - | ||
| Q4 2023 | -0.12 | -0.23 | 48.88% | 61.29% | - | - | ||
| Q3 2023 | -0.18 | -0.23 | 22.46% | 33.33% | - | - | ||
| Q2 2023 | -0.23 | -0.27 | 15.13% | 32.35% | - | - | ||
| Q1 2023 | -0.23 | -0.32 | 27.32% | - | - | - | ||
| Q4 2022 | -0.31 | -0.33 | 7.18% | - | - | - | ||
| Q3 2022 | -0.27 | -0.33 | 17.45% | - | - | - | ||
| Q2 2022 | -0.34 | -0.55 | 38.27% | - | - | - | ||
| Q1 2022 | - | - | - | - | ||||
| Q4 2021 | - | - | - | - | ||||
| Q3 2021 | - | - | - | - | ||||
| Q2 2021 | - | - | - | - | ||||
| Q1 2021 | - | - | - | - | ||||
| Q4 2020 | - | - | - | - |
Notes
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) last reported earnings on 1/8/2026.
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) beat EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, MOONLAKE IMMUNOTHERAPEUTICS (MLTX) has beaten EPS estimates in 2 out of 4 releases.